- Home
- LEXX vs HKPD Comparison
LEXX vs HKPD Comparison
Compare LEXX & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- HKPD
- Stock Information
- Founded
- LEXX 2004
- HKPD 2016
- Country
- LEXX Canada
- HKPD Hong Kong
- Employees
- LEXX N/A
- HKPD N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- HKPD Other Pharmaceuticals
- Sector
- LEXX Health Care
- HKPD Health Care
- Exchange
- LEXX Nasdaq
- HKPD Nasdaq
- Market Cap
- LEXX 23.9M
- HKPD 20.9M
- IPO Year
- LEXX N/A
- HKPD 2025
- Fundamental
- Price
- LEXX $0.82
- HKPD $1.25
- Analyst Decision
- LEXX Strong Buy
- HKPD
- Analyst Count
- LEXX 1
- HKPD 0
- Target Price
- LEXX $4.00
- HKPD N/A
- AVG Volume (30 Days)
- LEXX 1.3M
- HKPD 304.4K
- Earning Date
- LEXX 11-25-2025
- HKPD 08-14-2025
- Dividend Yield
- LEXX N/A
- HKPD N/A
- EPS Growth
- LEXX N/A
- HKPD N/A
- EPS
- LEXX N/A
- HKPD N/A
- Revenue
- LEXX $615,923.00
- HKPD $20,313,818.00
- Revenue This Year
- LEXX $46.98
- HKPD N/A
- Revenue Next Year
- LEXX $17.26
- HKPD N/A
- P/E Ratio
- LEXX N/A
- HKPD N/A
- Revenue Growth
- LEXX 49.85
- HKPD 21.72
- 52 Week Low
- LEXX $0.77
- HKPD $0.81
- 52 Week High
- LEXX $3.28
- HKPD $3.79
- Technical
- Relative Strength Index (RSI)
- LEXX 40.14
- HKPD 45.59
- Support Level
- LEXX $0.88
- HKPD $1.19
- Resistance Level
- LEXX $1.01
- HKPD $1.52
- Average True Range (ATR)
- LEXX 0.12
- HKPD 0.15
- MACD
- LEXX -0.06
- HKPD -0.03
- Stochastic Oscillator
- LEXX 3.11
- HKPD 10.32
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.